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Cytochrome P-450 (P450) enzymes in the mucosa of the alimentary tract may be involved in the activation and/or inactivation of 
ingested xenobiotics and procarcinogens. Since the multiple P450 enzymes have overlapping substrate specificities and, in some 
cases, similar antigenic determinants, definitive identification of P450 genes that are expressed in various tissues requires 
molecular analysis. In this study, a sensitive and specific polymerase chain reaction assay along with hybridization analysis was 
used to examine the expression of the CYP1A gene family in the rat alimentary tract. CYP1A1 mRNA was expressed throughout 
the alimentary tract in untreated rats, as determined by the polymerase chain reaction. However, Northern blot analysis detected 
CYP1A1 mRNA and enzymatic activity only in small intestine and liver, with greater amounts in intestine. After treatment with 
fl-naphthoflavone, CYP1A1 mRNA and enzymatic activity was markedly induced in each alimentary tissue including esophagus, 
fore-stomach, glandular stomach, small intestine and colon. A single dose of inducer resulted in a rapid rise in CYP1A1 mRNA 
which was shown by nuclear run-on assays to be primarily due to an increase in transcription of the CYP1A1 gene. CYPIA2 
mRNA was detected in significant amounts only in glandular stomach following induction although the polymerase chain 
reaction assay identified low levels of CYP1A2 mRNA in several other tissues. The definitive identification of the CYP1A genes 
that are expressed in alimentary tissue will allow the design of experiments to investigate the importance of these enzymes in the 
metabolism of carcinogens, and ultimately carcinogenesis, in the gastrointestinal tract. In addition, these data suggest the the 
aromatic hydrocarbon receptor, which mediates transcriptional induction of multiple genes by xenobiotics, is expressed throught 
the alimentary tract. 
Introduction 
The mucosal surfaces of the alimentary tract are 
continuously exposed to ingested xenobiotics (non- 
nutritive organic chemicals) including natural com- 
pounds synthesized by plants, industrial wastes, phar- 
maceutical agents and food additives. The metabolic 
fate of xenobiotics in the alimentary tract, many of 
which are proven or putative mutagens and carcino- 
gens [2,3], may be one determinant of tissue suscepti- 
bility for the development of intestinal cancer. Colon 
cancer is a common cause of mortality in the United 
States whereas cancer of the small intestine is rare [4]. 
Animal studies have substantiated the fundamental 
difference between the susceptiblity of these two tis- 
sues to carcinogenesis [5]. The risk of colon cancer may 
depend on dietary constituents which may contain ei- 
ther procarcinogens or compounds that modulate the 
response to carcinogens [6,7]. 
The majority of carcinogens require activation by 
cellular enzyme systems before they manifest muta- 
genic properties [8,9]. Although the metabolic path- 
ways for procarcinogens are complex, enzymes that are 
members of the cytochrome P-450 superfamily [1] are 
often crucial in either activation or inactivation [8,9]. 
The CYP1A subfamily 1 plays an integral role in 
metabolism of two important classes of environmental 
carcinogens, polycyclic aromatic hydrocarbons [10] and 
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Cytochrome P-450 genes in this report are named according to the 
recent recommendations for the standardization of P450 gene 
nomenclature [1]. Italicized CYP for cytochrome P-450 refers to 
the P450 gene or cDNA and non-italicized CYP refers to the P450 
mRNA or protein. CYPIAI and CYPIA2 in rat were previously 
referred to as P450IA1 or P450c and P4501A2 or P450d, respec- 
tively. 
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aryl amines [11]. PAHs are commonly present in the 
environment as a result of industrial combustion pro- 
cesses [12] and in tobacco products [13]. Several potent 
carcinogenic aryl amines result from the pyrolysis of 
amino acids in cooked meats which have been impli- 
cated as mutagens [14,15] and can cause colon cancer 
in rats [16]. 
The CYP1A subfamily of genes appears to contain 
two members in mouse, rat, rabbit and man, CYP1A1 
and CYP1A2 [1]. Expression of cDNAs in mammalian 
cells have determined that CYP1A1 is primarily re- 
sponsible for AHH activity and CYP1A2 is responsible 
for activation of aryl amines [17-19]. Environmental 
and genetic factors alter the expression of these en- 
zymes. Exposure to plant-derived chemicals and other 
xenobiotics causes an increase in these enzymes in liver 
and, for CYP1A1, in extrahepatic tissues [20,21]. It was 
recently reported that a human polymorphism of the 
CYP1A1 gene was associated with the development of 
lung cancers [22]. These findings suggest that genetic 
factors may be important in the expression of this gene 
in humans and that CYP1A1 may be involved in car- 
cinogenesis in humans. 
AHH activity has been identified in the small intes- 
tine of rat [23,24], rabbit [25] mouse [26] and man [27], 
and in the colon of rat [28]. However, few studies have 
definitively identified the specific P450 protein respon- 
sible for the enzymatic activity in the alimentary tract. 
The importance of this was highlighted by studies that 
suggested enzymatic activity of rat CYP1A enzymes 
may vary from one tissue to another [23]. Goldstein 
and Linko [29] identified CYP1A1 protein in rat small 
intestine and Vang et al. [30] were able to induce 
CYP1A1 mRNA in rat colon by treatment with indole- 
3-carbinol and /3-naphthoflavone. However, no system- 
atic study of the expression of CYP1A genes has been 
undertaken in the rat alimentary tract and no informa- 
tion is available on mechanisms of induction. 
The goals of this study were to definitively identify 
CYP1A genes expressed in the alimentary tract of rat, 
to determine if xenobiotics induce these genes, and to 
investigate the mechanisms of induction. Several chem- 
ical inducers of CYP1A genes were used in these 
studies including, /3-naphthoflavone a non-carcino- 
genic inducer which is related to dietary flavones, 
3-methylcholanthrene a carcinogenic hydrocarbon and 
prototypical inducer of CYPIA genes, and isosafrole a 
non-carcinogenic dietary compound that also induces 
CYP1A genes. Each of these classes of compounds are 
encountered by humans in the environment albeit at 
lower levels than used for the purposes of this study. 
Other chemicals were used to assess for the specificity 
of the responses including phenobarbital and dexa- 
methasone, known inducers of other CYP genes. 
CYP1A mRNA was evaluated by a highly sensitive and 
specific polymerase chain reaction (PCR) assay and by 
hybridization analysis using probes that discriminate 
between CYP1A1 and CYP1A2 mRNAs; induction of 
mRNA was correlated with enzymatic activity. The 
mechanism of induction of CYP1A gene expression 
was evaluated by using nuclear run-on assays. 
Materials and Methods 
Materials 
Guanidinium isothiocyanate, cesium chloride, T4 
polynucleotide kinase, Klenow enzyme and T4 ligase 
were obtained from Bethesda Research Laboratories 
(Gaithersburg, MD). [32p]dCTP (>3000  Ci/mmol),  
[3ep]ATP (>5000  Ci/mmol),  [35S]dATP (1000 C i /  
mmol), Hybond-N nylon membranes an were obtained 
from Amersham (Arlington Heights, IL). Oligo(dT) 
cellulose was obtained from Pharamcia. AMV reverse 
transcriptase, all restriction enzymes, oligo(dTls) and 
dideoxynucleotides were obtained from Boehringer- 
Mannheim (Germany). Taq polymerase was purchased 
from Perkin Elmer-Cetus (Norwalk, CT). Oligonucleo- 
tides were synthesized by the University of Michigan 
Gastrointestinal Peptide Hormone Center's oligo- 
nucleotide synthesis facility. NuSieve, SeaKem and 
SeaPlaque agaroses were obtained from FMC Bio- 
chemical (Rockland, ME). Escherichia coli RNA was 
purchased from Calbiochem. All other chemicals were 
obtained from Sigma (St. Louis, MO). 
Animals 
Male F344 rats weighing 200-250 g were housed in 
wire-floored cages and had free access to standard 
laboratory rat chow and water. The procedures used in 
these experiments were approved by the Animal Use 
Committee of the University of Michigan. Animals 
were treated with one of the following regimens: 
phenobarbital (80 mg/kg)  administered daily for 3 days 
by intraperitoneal injection; BNF (80 mg/kg)  adminis- 
tered daily for 3 days by intraperitoneal injection; 
3-MC (20 mg/kg)  as a single intraperitoneal dose; 
dexamethasone (20 mg/kg)  as a single intraperitoneal 
dose; a combination of phenobarbital and dexametha- 
sone; isosafrole (80 mg/kg).  Control animals (or 'un- 
treated'  rats) were injected with corn oil alone since 
this was used as a vehicle for administration of each of 
the inducers except for phenobarbital which was dis- 
solved in 0.15 M NaC1. 
RNA extraction and Northern blot analysis 
Livers and the entire gastrointestinal tracts were 
removed from rats that had been anesthetized by di- 
ethyl ether inhalation. A portion of each liver was 
immediately frozen in liquid nitrogen and the gastro- 
intestinal tissue was thoroughly washed with ice-cold 
0.15 M NaCI. Esophageal mucosa was obtained by 
eversion and stripping of the mucosa from the muscu- 
lar layer; mucosa from the forestomach, glandular 
stomach, small intestine and colon was obtained by 
scraping using a glass slide. RNA was extracted as 
described by Chomczynski and Sacchi [31]. Polyadeny- 
lated RNA was isolated from aliquots of total RNA 
using using a microbatch method as previously de- 
scribed [32]. Samples of either total or polyadenylated 
RNA were size separated by electrophoresis in 2.2 M 
formaldehyde agarose gels. The RNA was transferred 
to Hybond-N (Amersham) nylon membranes by an 
electroblotting method and crosslinked to the mem- 
branes using ultraviolet radiation. The membranes were 
prehybridized, hybridized and washed as previously 
described [33]. 
DNA probes 
A CYP1A1 cDNA probe, p210, and a CYP1A2 
cDNA which were cloned from rat liver were gifts of 
Dr. J. Fagan (Fairfield, IA [34]). A full-length P450 
reductase cDNA, pSP65-OR, that was cloned from rat 
liver was a gift of Dr. C. Kasper (Madison, WI [35]). 
Control cDNAs used in nuclear run-on experiments 
included a human /3-actin cDNA, pHFBA-1 and an 
18S ribosomal RNA cDNA have been used previously 
in our laboratory [32]. The cDNAs that were used in 
Northern blots were isolated from their plasmid vec- 
tors and radiolabeled with [a-32p]dCTP using a ran- 
dom-primed oligonucleotide labeling method as previ- 
ously described [33,36]. Oligonucleotides were 5'- 
labeled with [32p]ATP using T 4 polynucleotide kinase 
as previously described [32,36]. Unincorporated nu- 
cleotides were removed from the labeled DNA using 
Sephadex G-50 chromatography (Nick columns, Phar- 
macia, Uppsala, Sweden). 
The oligonucleotides used in this study were de- 
signed using the rat cDNA sequences as published by 
Kawajiri et al. [37] for CYPIA2 and by Sogawa et al. 
[38] for CYP1A1. 
P450|A2: 
5' PCR primer: [5'-GGTGGTCTCATCCCTCAGGA-3'] 
3' PCR primer: [5'-TTTATGAAGATGCAGCACTC-3'] 
Nested probe: [5'-GGATGTGTATCGGTAGAT-3'] 
P450IAl: 
5' PCR primer: [5 '-GTAACCAACCCTAGGATACA-3'] 
3' PCR primer: [5'-TTCACAAAGACACAGTGTCC-3'] 
Nested probe: [5'-GGATGAATGTCGTGGAAGGT-3'] 
Enzymatic amplification and identification of mRNA 
Complementary DNA was synthesized from total 
RNA using oligo(dTl5) (1 tzg) as a primer and AMV 
reverse transcriptase (13 U/reaction) in a total reac- 
tion volume of 50/xl containing 50 mM Tris-HC1 (pH 
8.3), 50 mM KCI, 8 mM MgCI2, 10 mM dithiothreitol, 
and 0.5 mM each of dATP, dCTP, dGTP and dTT. 
The reaction mixture, without the reverse transcrip- 
tase, was incubated at 41°C for 15 min; the reverse 
transcriptase was then added and the reaction allowed 
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to proceed for 1 h at 41°C. Segments of the CYP1A 
cDNAs were enzymatically amplified using oligo- 
nucleotide primers and PCR. 20 /zl of the cDNA 
synthesis reaction mixture was amplified using 1 ~M of 
each oligonucleotide primer (20mers) and 2.5 U of Taq 
polymerase in a total reaction volume of 100 #1 con- 
taining 10 mM Tris-HC1 (pH 8.3), 50 mM KCI, 1.5 mM 
MgC1 z, 2 mM dithiothreitol, 0.01% gelatin and 200 
txM each of dATP, dCTP, dGTP and dTTP. The 
reaction mixture was overlaid with 100 tzl of mineral 
oil and subjected to 30 cycles of amplification. The 
samples were cycled as previously described [32] using 
55°C as the annealing temperature. 
10 /zl of the PCR mixture was separated in 3% 
NuSieve and 1% SeaKem agarose gels containing 
ethidium bromide (0.5 /z/ml)  using a Tr is /  
borate/EDTA buffer. After photography, the DNA 
was electrophoretically transferred to Hybond N nylon 
membranes and the DNA was bound to the nylon 
using ultraviolet radiation crosslinking. The mem- 
branes were prehybridized and hybridized with a 5'- 
labeled oligonucleotide probe ('nested probe') and 
washed as previously described [32]. The temperature 
of hybridization was performed at the hypothetical 
temperature of dissociation of DNA:DNA hybrids 
(approx. 55°C) for the oligonucleotide to maximize the 
specificity of hybridization. 
Nuclear run-on assay 
Nuclear run-on assays were performed as previously 
described [32]. Mucosal scrapings were washed twice in 
ice-cold 0.15 M NaC1, 5 mM DTT and resuspended in 
nuclei lysis buffer (NLB : 10 mM Tris-HC1 (pH 7.4), 10 
mM NaCI, 5 mM DTF). The suspension was homoge- 
nized in a Dounce homogenizer using 10 strokes of the 
loose pestle, then 10 strokes of the tight pestle and 
centrifuged at 800 × g and 4°C for 10 min. The result- 
ing pellet was resuspended in sucrose buffer (2.4 M 
sucrose, 1 mM CaCle, 5 mM DTT) by vortexing and 
centrifuged at 50000 ×g  at 4°C for 1 h. The pellet 
containing the purified nuclei was resuspended in nu- 
clei storage buffer (NSB: 40% glycerol, 50 mM Tris-HCl 
(pH 8.3), 0.1 mM EDTA and 5 mM MgC12), an aliquot 
counted in a hemacytometer and frozen at -80°C. 
Transcription reactions were initiated by adding 60 
/zl of 5 × run-on buffer (25 mM Tris-HCl (pH 8.0), 12.5 
mM MgCl2, 750 mM KC1 and 1.25 mM each of ATP, 
GTP and CTP) and 30 #1 of [32p]UTP (>3000 
Ci/mmol, 10 /xCi//xl) to 210 /xl of NSB containing 
approx. 5 • 107 nuclei. Following incubation at 30°C for 
30 min, the labeled RNA transcripts were isolated as 
described [32]. 
Plasmids containing the cDNAs of interest were 
denatured by heating in 0.2 M NaOH and applied to 
nitrocellulose using a Minifold II slot blot device 
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Fig. I. PCR analysis for expression of CYP1AI mRNA. RNA was extracted from liver and alimentary tract tissues from control rats and rats 
treated with BNF. Reverse transcription and PCR was performed as described in Materials and Methods and the products analyzed on a 3% 
NuSieve, 1% SeaKem agarose gel (A). The DNA was transfered to nylon membrane and hybridized with an end-labeled nested oligonucleotide 
which is complementary to CYP1A1 as described in methods (B). First lane on gel contains size markers. The expected size band for CYP1AI 
mRNA is 230 base pairs. The 470 base pair band represents amplification of a small amount of contaminating genomic DNA which includes and 
intron. 
used: pSBF1 (previously cloned in our  laboratory [32]), 
p210 (CYP1A1 c D N A  probe),  pSP450OR (P450 reduc- 
tase cDNA),  pHFBA-1  (human  /3-actin cDNA),  p rA 
(human  18S ribosomal R N A  cDNA)  and the bacterial  
vector p G E M  which served as a negative control  for 
non-specific binding.  The  ni trocel lulose conta in ing  the 
bound  cDNAs was prehybridized at 60°C for 8 h in a 
solution conta in ing  10 mM Tes (pH 7.4), 0.2% SDS, 10 
mM EDTA,  0.3 M NaCl, 1 × Denha rd t ' s  solut ion and 
5 / x g / m l  E. coli RNA.  This solut ion was replaced with 
2 ml of the same solut ion conta in ing  1 • 107 c p m / m l  of 
labeled R N A  transcripts  and hybridizat ion con t inued  
for 36 h (cpms were equal ized for each sample of 
nuclei). The  membranes  were washed in three changes 
of 0.1 × SSC and 0.1% SDS at the hybridizat ion tem- 
perature .  Following autoradiography,  the blots were 
quan t i t a ted  using a Betascope 603 Blot Analyzer.  Since 
there was variat ion in the n u m b e r  of nuclei  used in the 
reaction,  the results of the t ranscr ipt ion react ion were 
normal ized  for hybridizat ion to the r ibosomal R N A  
A. 
cDNA; this correlated with the D N A  concent ra t ion  of 
the nuclear  preparat ion.  
Enzyme assays 
The mucosal  l ining of each organ was scraped with a 
glass slide and microsomes were isolated as previously 
described [36]. Protein  concent ra t ions  in the micro- 
somes were measured  by the method  of Lowry [39]. 
The  ability of microsomes to dealkylate ethoxyre- 
sorufin was used as an enzymatic  assay for P450c 
(CYP1A1) and was per formed as described by Buke et 
al. [40]. This assay has been  shown to be specific for rat 
P450c al though there is some minimal  overlap with 
P450d (CYP1A2) [41]; there is no overlap with six other  
forms of P450 [41]. 
Resu l t s  
Identification of CYP1A mRNA by PCR 
The first goal of this study was to definitively iden- 
tify the CYP1A m R N A s  that are constitutively ex- 
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Fig. 2. PCR analysis for expression of CYP1A2 mRNA. RNA was extracted from liver and alimentary tract tissues from control rats and rats 
treated with BNF. Reverse transcription and PCR was performed as described in Materials and Methods and the products analyzed on a 3% 
NuSieve, 1% SeaKem agarose gel (A). The DNA was transfered to nylon membrane and hybridized with an end-labeled nested oligonucleotide 
which is complementary to CYP1A2 as described in methods (B). First lane on gel contains size markers. The expected size band for CYPIA1 
mRNA is 336 base pairs. The smaller band noted on the Southern blot represents amplification of single stranded cDNA as previously 
determined [32]. 
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pressed and inducible in tissues of the rat alimentary 
tract. Rats were treated with intraperitoneal injections 
of either corn oil alone or with 80 mg /kg  of BNF for 3 
consecutive days. RNA was extracted from mucosa of 
esophagus, fore-stomach, glandular stomach, jejunum 
and colon as well as from liver. Oligo(dT)-primed 
cDNA was synthesized from total RNA and used to 
amplify CYP1A1 or CYP1A2 sequences. The segment 
amplified spanned an intron to avoid false positive 
results that would occur by amplification of genomic 
DNA which might contaminate the RNA samples. 
When RNA from control and treated tissues was 
assayed, a DNA fragment of the expected size for 
CYP1A1 was amplified (Fig. 1). An oligonucleotide 
complementary to the sequence of CYP1A1 mRNA 
between the two PCR primers ( 'nested oligonucleo- 
tide') hyhridized to the amplified DNA fragment; this 
analysis verifies that the correct sequence was ampli- 
fied and, additionally, increases the sensitivity for de- 
tection of amplified product. In a number of samples a 
470 bp fragment was identified which corresponds to 
the expected size of amplified genomic DNA. When 
the CYP1A2-specific primers were used, a fragment of 
the expected size (336 bp) was found in the glandular 
stomach and small intestine of animals treated with 
BNF (Fig. 2). Small amounts of CYP1A2 mRNA were 
detected in control and treated esophagus and fore- 
stomach and in control glandular stomach and je- 
junum; the colon contained no CYP1A2 mRNA. The 
second band detected on the Southern blot represents 
amplification of single-stranded DNA as a result of 
asymmetric amounts of primers as we and others have 
previously demonstrated [32]; this band does not repre- 
sent amplification of CYPIA1 as it did not hybridized 
to the CYP1A1 probe (data not shown) and is of 
greater size than expected. 
Quantitatit~e analysis of CYP1A mRNA 
Northern blot analysis was used to quantitate rela- 
tive levels of CYPIA1 and CYPIA2 mRNAs. The 
cDNA probes used for this analysis have been shown 
to distinguish between the two mRNAs [34]. Rats were 
treated with three daily intraperitoneal injections of 
corn oil (control), BNF (80 mg/kg),  phenobarbital (80 
mg/kg),  dexamethasone (300 mg/kg,  single dose), or a 
combination of phenobarbital and dexamethasone. 
Phenobarbital and dexamethasone were included in 
this analysis to evaluate for specificity of the response 
of CYP1A1 genes. The CYP1A1 cDNA hybridized to a 
2.8 kb band from RNA isolated from control jejunum 
and from BNF-treated mucosa from each of the tissues 
(Fig. 3). It should be noted that the intensity of the 
band in untreated jejunum was greater than that in 
liver RNA. 
When the CYP1A2 cDNA was hybridized to a simi- 
lar blot, only the liver RNA from a BNF treated 
animal had the expected 2.1 kb band (data not shown). 
In order to maximize the induction of and detection of 
CYP1A2 mRNA, rats were treated with intraperi- 
toneal and intragastric doses of isosafrole (80 mg/kg),  
a potent inducer of CYP1A2 in rat liver [42]. This 
inducer and route of administration was chosen to 
maximize the possiblity of inducing CYP1A2. Northern 
blots of polyadenylated RNA isolated from these ani- 
COLON JEJUNUM LIVER 
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Fig. 3. Northern blot analysis for expression of  CYP1A! mRNA. RNA was extracted from liver and alimentary tract tissues from control rats (C) 
and rats treated with BNF, dexamethasone (DEX), phenobarbital (PB), or a combination of PB and DEX. 10 p,g of RNA was separated in a 1% 
agarose, 2.2 M formaldehyde gel, transfered to nylon membrane  and hybridized with 32p-labeled p210 cDNA as described in Materials and 
Methods. The upper and lower panels represent  different exposure times and, therefore, the intensity of bands are not comparable as indicated 
by the intensity of the bands in induced liver. 
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Fig. 4. Northern blot analysis for expression of CYP1A2 mRNA.  
Polyadenylated RNA was extracted from stomach (S), je junum (J) 
and colon (C) from untreated rats and rats treated with isosafrole. 10 
/~g of polyadenylated RNA was separated in a 1% agarose, 2.2 M 
formaldehyde gel, transfered to nylon membrane  and hybridized with 
32P-labeled p72 cDNA as described in Materials and Methods. After 
autoradiography, the blot was stripped of the probe and rehybridized 
with 32P-labeled /3-actin cDNA. Sizes of the bands were calculated 
from size markers run on the same gel. 
reals d e m o n s t r a t e d  that  CYP1A2  m R N A  was induced  
in g l andu la r  somach,  but  not  j e junum or  colon (Fig. 4). 
Rehybr id iza t ion  of  the  same blot  with /3-actin c D N A  
showed that ,  a l though the re  were  t issue-specif ic  differ-  
ences in the  /3-actin m R N A  levels, s imilar  amoun t s  of  
R N A  were  p resen t  for each tissue (Fig. 4). 
Induction of enzyme actiuity 
Ethoxyresoruf in  dee thy lase  ( E R D E )  activity has 
been  shown to be rela t ively specific for CYP1A1 [40,41]. 
There fo re ,  E R D E  activity was assayed in micosomes  
isola ted  from u n t r e a t e d  and B N F - t r e a t e d  animals  (Fig. 
5). E R D E  activity was grea tes t  in j e junum of  control  
rats  with a low level in cont ro l  liver and  no de t ec t ab l e  
activity in the  r e m a i n d e r  of  the  a l imenta ry  t ract .  Fol-  
lowing t r e a t m e n t  with BNF,  E R D E  activity was in- 
c reased  in each a l imenta ry  t ract  t issue (Fig. 5). The re -  
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Fig. 5. Ethoxyresorufin deethylase activity in liver and alimentary 
tract microsomes. Microsomes were isolated from esophagus (E), 
fore-stomach (FS), glandular stomach (GS), je junum (J), colon (C) 
and liver (L) from control and BNF-treated animals. E R D E  activity 
was determined in duplicate as described in Materials and Methods.  
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Fig. 6. Time course of induction of CYP1A1 mRNA in small intesti- 
nal mucosa. RNA was isolated from small intestinal mucosa of 
untreated rats and 3, 6, 12 and 24 h following a single intraperitoneal 
injection of 3-methylcholanthrene (20 mg/mg body weight). North- 
ern blot analysis was performed as described in methods using the 
p210 cDNA as a probe. Top panel shows ethidium-bromide stained 
gel and lower panel shows audoradiograph after hybridization. Com- 
plete transfer of the RNA to the nylon membrane was confirmed by 
UV illumination of the membrane after transfer and restaining of 
the gel. The lower graph shows densitometric analysis of CYPIAI 
mRNA normalized for the density of ribosomal RNA as determined 
from the ethidium bromide stained gel. 
fore,  the  pa t t e rn  of  const i tut ive  and induced  enzymat ic  
activity was s imilar  to the  pa t t e rn  of  CYP1A1 m R N A  
expression.  
Route of administration of inducer 
The  a f o r e m e n t i o n e d  exper imen t s  were  p e r f o r m e d  
using in t r ape r i t onea l  inject ions of  the  inducers  since 
systemic admins t r a t ion  was felt  to be the most  consis- 
tent  m e t h o d  of  admin is t ra t ion .  To d e t e r m i n e  if s imilar  
resul ts  were  ob t a ined  by in t ragas t r ic  admin is t ra t ion ,  
rats  were  given 3-MC (20 m g / k g )  by e i ther  in t raper i -  
tonea l  or  in t ragas t r ic  inject ion and mic rosomes  isola ted  
f rom je juna l  mucosa  16 h later .  3 -MC was used in these  
exper imen t s  since this inducer  y ie led  s imilar  induct ion  
in the  ent i re  a l imenta ry  t ract  as did  BNF.  In control  
animals  the  level of  resoruf in  dee thy lase  activity was 
0.109 _+ 0.53 pmol  resoruf in  p r o d u c e d / / ~ g  p ro te in  pe r  
min. This  activity inc reased  in animals  t r ea t ed  with 
bo th  in t r ape r i tonea l  and in t ragas t r ic  inject ions of  3-MC 
to 0.516 _+ 0.179 and 0.814 _+ 0.098 pmol resorufin pro- 
d u c e d / ~ g  protein per min, respectively. The greater 
induction by the intragastric route may be due to a 
higher dose of inducer reaching the intestinal mucosa. 
This demonstrates that both routes of administration 
induce enzymatic activity; CYP1A1 m R N A  was simi- 
larly increased by both routes (data not shown). 
Mechanism of induction of mRNA in small intestine 
Northern blot analysis suggested that the major level 
of regulation for CYP1A1 induction was alteration in 
the steady-state level of CYP1A1 mRNA. Therefore, 
further experiments were performed to determine if 
induction of gene transcription was responsible for the 
observed increase in CYP1A1 mRNA. Following a 
single dose of 3-MC there was a prompt increase in 
CYP1A1 m R N A  by 3 h and levels remained relatively 
stable for 24 h (Fig. 6); BNF gave a similar pattern of 
induction as did intragastric administration (data not 
shown). Therefore, transcriptional assays were per- 
formed 6 h following injection. Nuclear run-on assays 
were performed using nuclei isolated from jejunal mu- 
cosa from rats treated with corn oil (controls), 3-MC 
(20 mg/kg)  and isosafrole (80 mg/kg).  Fig. 7 demon- 
strates that there was approx. 6-fold induction of 
CYP1A1 gene transcription following 3-MC treatment 
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which was roughly equivalent to the increase in 
CYP1A1 m R N A  (Fig. 6). These data indicate that, at 
least in part, the induction of CYP1A1 m R N A  is due 
to an increase in gene transcription. 
Discussion 
CYP1A1 mRNA and enzymatic activity were pre- 
sent in the small intestinal mucosa of untreated rats, at 
levels greater than those in liver. Expression of CYP1A1 
in untreated jejunal mucosa may represent constitutive 
expression or the inductive effect of low levels of 
chemical inducers in the rat chow. The PCR assay also 
indicated that CYP1A1 m R N A  was constitutively ex- 
pressed in the other gastrointestinal tissues studied. 
Because of the great sensitivity of PCR, constitutive 
levels of CYP1A1 m R N A  detected by PCR in tissues 
other than liver and small bowel represent very low 
levels of expression. The lack of detectable mRNA on 
northern analysis or enzymatic activity in these tissues 
suggests that the low levels of m R N A  may be of little 
biological significance; however, expression of CYP1A1 
in a small subset of cells could potentially be of func- 
tional importance. After treatment with BNF, CYP1A1 
mRNA and E R D E  activity were markedly induced 
throughout the gastrointestinal tract and in liver. The 
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UNTREATED 6h 3-MC 6h ISO 
Fig. 7. Nuclear run-on assays on small intestinal nuclei. Nuclei were isolated from small intestinal mucosa of untreated rats and rats treated with 
3-methylcholanthrene (3-MC) and isosafrole (ISO). Nuclear run on assays were performed as described in methods and transcripts hybridized to 
pGEM plasmid as a negative control, CYP2B1 eDNA, CYP1A1 cDNA-p210 and /3-actin eDNA. Counts over 30 min were measured using a 
Betascope counter. In the graph, counts for CYP1A1 were normalized for counts for fl-actin. The relative intensities of the actin and 18S 
ribosomal bands were comparable. Furthermore, as discussed in Materials and Methods, the intensity of the ribosomal and actin bands 
correlated with the amount of DNA (and hence nuclei) that were used in the individual reactions. 
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combined approach of PCR and Northern analysis 
provided complementary data. Northern analysis as- 
sessed the relative levels of mRNA and indicated the 
size of the mRNA. The PCR provided greater sensitiv- 
ity and, by hybridization with internal oligonucleotides, 
confirmed the identitiy of the amplified mRNAs. This 
was useful since hybridization of the Northern blots 
with cDNAs could potentially detect Other mRNAs 
with similar sequences. 
The mechanism of induction of CYP1A1 mRNA 
was further investigated using nuclear run-on studies. 
This assay provides a relative measure of the number 
of inititated primary transcripts at the time of isolation 
of the nuclei. The increased labeling of transcripts 
after a single dose of 3-MC suggests that an increase in 
transcription of the gene is responsible for a major 
portion of the increased CYP1A1 mRNA levels. 
Therefore, it appears that the mechanism for induction 
of the CYP1A1 gene in intestine is similar to that in 
liver. In hepatocytes, inducing agents bind to a cytoso- 
lic receptor protein, the Ah receptor, which is translo- 
cated to the nucleus and binds to DNA elements in the 
5'-flanking region of the CYP1A1 gene to enhance 
transcription [43,44]. Ah receptor-like binding activity 
has also been identified in small intestinal mucosa [45]. 
The presence of the Ah receptor in intestinal tissues 
may have implications beyond those of xenobiotic 
metabolism since it is responsible for induction of a 
battery of genes [46] and may play a role in the control 
of cellular growth and differentiation [47]. 
CYP1A2 mRNA was identified in several tissues of 
the gastrointestinal tract by PCR analysis. On North- 
ern blots CYP1A2 mRNA was detectable only in the 
glandular stomach after induction with isosafrole, a 
potent inducer of CYP1A2 in liver. A sufficiently sensi- 
tive and specific enzymatic assay is not available for 
CYPIA2 to determine if this mRNA is translated into 
active enzyme. Although levels of CYP1A2 mRNA 
were low in stomach it is possible that this expression 
represents significant levels for metabolism in a select 
population of ceils located within the gastric mucosa. If 
CYPIA2 is expressed only in a minority of these cells, 
localized levels of CYP1A2 might be high enough to 
activate or metabolize ingested carcinogens in those 
specific cells. This is a potentially important issue for 
gastric carcinogenesis since a number of ingested pro- 
carcinogens, notably aryl amines, require activation by 
CYP1A2 before they are mutagenic. It is of interest 
that recent data suggested that an increased risk of 
stomach cancer was associated with cigarette smoking 
[48] which can induce CYP1A2 in humans [21]. Previ- 
ous studies in rat [29,49,50] or human [50] have not 
identified CYP1A2 in extrahepatic tissues; however, 
this study represents the first evaluation for expression 
in stomach. In contrast, P3450 mRNA, the mouse 
CYP1A2 ortholog, was expressed and inducible in mul- 
tiple mouse tissues including liver, spleen, lung, kidney, 
small intestine and colon [26]. Therefore, there are 
important species differences in the extrahepatic ex- 
pression of the CYP1A2 gene. 
The observed pattern of expression of CYP1A1 
mRNA and enzymatic activity allows speculation as to 
the significance of these findings for the resistence of 
the small intestine to carcinogenesis. The fact that 
CYPIA1  is expressed constitutively only in the small 
intestine raises the question of whether this enzyme 
provides a protective mechanism for the mucosa. Pre- 
treatment with inducers of CYP1A1 has been shown to 
provide a protective effect for subsequent administra- 
tion of carcinogens in other tissues [51,52]. Although 
CYP1A1 itself may be responsible for this effect, en- 
zymes that are co-regulated with CYP1A1 may be 
more important. CYP1A1 may metabolize procarcino- 
gens to inactive compounds which are not mutagenic. 
This might occur with colonic carcinogens such as 
2-amino-3,4-dimethylimidazo[4,5-f]quinoline which may 
be inactivated by CYP1A1 through ring hydroxylation 
as are other aromatic amines [8]. Although inactivation 
of procarcinogens is plausible, it does not explain how 
the small bowel protects itself from ingested com- 
pounds that are known to be activated by CYPIA1 
such as polycyclic aromatic hydrocarbons. One possible 
explaination for this paradox might be the distribution 
of CYP1A1 in the small intestinal mucosa. The epithe- 
lial lining of the small intestine is continually renewed 
by division of a stem-cell population located in intesti- 
nal crypts, migration of daughter cells along the villus 
and, finally extrusion of senescent cells into the intesti- 
nal lumen. As the cells migrate from the crypt zone 
onto the villus, they cease cell to proliferate and ac- 
quire differentiated functions. We previously demon- 
strated that CYP2B1 mRNA was only expressed in the 
differentiated villus cells [36] and others have shown 
that CYP1A1 protein [53] or enzymatic activity [54] is 
expressed in the same cells. Additional data from our 
laboratory showed that CYP1A1 mRNA was expressed 
in villus cells constitutively, but was inducible in crypt 
cells after intraperitoneal injection of 3-MC [55]. It is 
conceivable that procarcinogens activated in the non- 
proliferating villus cells would bind to DNA in these 
cells and, without further division, mutations in DNA 
would not occur. Since the villus cells are destined for 
extrusion into the intestinal lumen, binding of muta- 
gens to the DNA in villus cells can be viewed as a 
detoxification process. This possibility requires further 
investigation. 
In conclusion, we have identified members of the 
CYP1A family that are expressed constitutively and are 
inducible along the entire length of the rat gastrointes- 
tinal tract. Further investigation of CYP1A1 expression 
in the gastrointestinal tract and CYP1A2 expression in 
stomach will be directed towards the role of these 
enzymes in metabolism of ingested xenobiotics and 
carcinogens as well as the possible role of Ah receptor 
in cellular proliferation and differentiation. 
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